Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07816380Phase 3Not yet recruiting
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Oct 2026
- Primary completion
- Dec 2028
01
Overview
Phase 3, randomised, open-label trial of JYP0322 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Progression-Free Survival at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
JYP0322
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07816380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816380.